Connect Sign In
Chromogranin A, Serum
Ordering Recommendation
Aids in monitoring but is not recommended for diagnosis of carcinoid tumors. May be useful in monitoring nonsecretory sympathetic and parasympathetic neuroendocrine tumors.
Methodology
Immunofluorescence
Performed
Sun, Mon, Wed, Fri
Reported
1-5 days
New York DOH Approval Status
Specimen Required
Serum separator tube or plain red.
Allow serum specimen to clot completely at room temperature. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Frozen.
Plasma.
After separation from cells: Ambient: 48 hours; Refrigerated: 3 days; Frozen: 4 weeks
Reference Interval
0-103 ng/mL
Interpretive Data
This test is performed using the BRAHMS CGA II Kryptor kit. Results obtained with different methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.
Nontumor-related elevations of Chromogranin A can be observed in gastrointestinal, cardiovascular, and renal disorders, as well as with proton pump inhibitor (PPI) therapy. It is recommended to stop PPI treatment for at least two weeks prior to testing. Moderate H2-receptor antagonist therapy does not lead to significant elevations of Chromogranin A.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Note
Hotline History
CPT Codes
86316
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 3002868 | Chromogranin in serum | 9811-1 |
Aliases
- CgA
Feedback
